ライフサイエンスコーパス: idarubicin

1 icity was rare after induction (4 L-DNR vs 5 idarubicin).

2 also appears to add potency and selectivity (idarubicin).

3 mage following treatment with cytarabine and idarubicin.

4 t with ATRA and arsenic trioxide or ATRA and idarubicin.

5 rug doxorubicin, but not by the related drug idarubicin.

6 , granulocyte colony-stimulating factor, and idarubicin.

7 5-drug reinduction or fludarabine/cytarabine/idarubicin.

8 hen combined with cytarabine (ara-C) or with idarubicin.

9 yl-l-leucinal (MG-132) and the anthracycline idarubicin.

10 ce to mitoxantrone and topotecan, but not to idarubicin.

11 served in a previous study using oral ATRA + idarubicin.

12 A regimen [cladribine, high-dose cytarabine, idarubicin]).

13 icroM) and VPA (0.25 mM) in combination with idarubicin (0.5 nM) resulted in a significant increase i

14 aged 60 years) intravenously on days 1-5 and idarubicin (10 mg/m(2)) intravenously on days 1-3.

15 tients, 216 were randomly assigned to either idarubicin (109 analysed) or mitoxantrone (103 analysed)

16 .0 mg/m(2)/d IV over 2 hours on days 1 to 5, idarubicin 12 mg/m(2) by 5 minute IV infusion on days 1

17 Chemotherapy (idarubicin 12 mg/m(2) daily days 1-2 for 2 courses) was

18 days 1-4 (3 days in patients >60 years) and idarubicin 12 mg/m(2) daily on days 1-3.

19 ional cytarabine 100 mg/m(2) on days 1-5 and idarubicin 12 mg/m(2) intravenously on days 2-3 (ie, 5 +

20 l complete remission (CR), with two doses of idarubicin 12 mg/m(2) on days 1 and 3, followed by conso

21 duction with ATRA 45 mg/m(2) twice daily and idarubicin 12 mg/m(2) once daily on days 1, 3, 5, and 7,

22 acycline (daunorubicin 60 mg/m(2) per day or idarubicin 12 mg/m(2) per day) by intravenous infusion o

23 anthracycline (daunorubicin 60-90 mg/m(2) or idarubicin 12 mg/m(2), once daily) on days 1-3 followed

24 ate, and prednisone (POMP) with one cycle of idarubicin 12 mg/m2 daily for 2 days.

25 Patients in CR received two courses of idarubicin 12 mg/m2 daily for 3 days and then, until 2 y

26 ays 4-10) combined with intensive induction: idarubicin 12 mg/m2 on days 1 to 3 plus either cytarabin

27 A dose of idarubicin 12 mg/m2/d for 3 days given in combination wi

28 ) per dose for eight doses), with or without idarubicin (12 mg/m(2) as a single dose).

29 er day on days 1-7) and intravenous bolus of idarubicin (12 mg/m(2) per day on days 1-3).

30 for eight doses, with or without intravenous idarubicin (12 mg/m(2)) as a single dose, using a rollin

31 -related mortality was lower with L-DNR than idarubicin (2/257 vs 10/264 patients, P = .04).

32 uproleselan at the RP2D plus cytarabine and idarubicin (7 + 3).

33 eceived six reinduction courses, alternating idarubicin 8 mg/m(2) on day 1, cytarabine 100 mg/m(2) on

34 Induction therapy included idarubicin 8 mg/m(2) on days 1 to 5, cytarabine 100 mg/m

35 days), cytarabine (2 g/m(2) for 5 days), and idarubicin (8 mg/m(2) for 3 days), and subcutaneous gran

36 for patients aged 60 years) on days 1-3 and idarubicin (8 mg/m(2)) on days 1-2.

37 , etoposide 75 mg/m(2) daily for 5 days, and idarubicin 9 mg/m(2) daily for either 2 or 3 days (stand

38 atients received All-trans retinoic acid and idarubicin according to the GIMEMA protocols AIDA-0493 a

39 s with AML in the phase II portion (12 mg/m2 idarubicin) achieved a complete remission (CR).

40 darubicin and anthracycline (composed of the idarubicin aglycon and the aclarubicin trisaccharide) st

41 Among these, N,N-dimethyl-idarubicin and anthracycline (composed of the idarubicin

42 Patients were randomized to receive idarubicin and ara-C (IA) versus troxacitabine and ara-C

43 ition of nivolumab to frontline therapy with idarubicin and cytarabine in patients with newly diagnos

44 of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with n

45 The combination of vorinostat with idarubicin and cytarabine is safe and active in AML.

46 e 1-2 study of nivolumab in combination with idarubicin and cytarabine was done at the University of

47 consolidation cycles of attenuated doses of idarubicin and cytarabine, or allogeneic stem cell trans

48 cone), carminomycin, 13-dihydrocarminomycin, idarubicin, and aklavin were not apparent substrates for

49 ycline analogues: doxorubicin, daunorubicin, idarubicin, and epirubicin for their ability to inhibit

50 ed anthracycline agents (e.g., daunorubicin, idarubicin, and epirubicin) significantly upregulated th

51 boplatin, alternating with cyclophosphamide, idarubicin, and vincristine, for stage III retinoblastom

52 toposide, alternating with cyclophosphamide, idarubicin, and vincristine.

53 arubicin are superior to regimens containing idarubicin + ara-C (IA) without either fludarabine or to

54 + ara-C (TA) or fludarabine + ara-C (FA) +/- idarubicin are superior to regimens containing idarubici

55 rednisone), ALLG APML4 (single arm of ATRA + idarubicin + arsenic trioxide + prednisone), CALGB C9710

56 ly for 4 days (3 days if > 60 years of age), idarubicin at 12 mg/m(2) IV daily for 3 days, and sorafe

57 e at 10 mg/m(2) on days 1-4 of course 3, and idarubicin at 12 mg/m(2) on day 1 of the final (fourth)

58 ed fludarabine at 30 mg/m2/d for 4 days with idarubicin at 12 mg/m2/d for 3 days and ara-c at 2 g/m2/

59 ardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a higher-than-equivalent dose (80 vs 12 mg

60 duction, ATO was superimposed on an ATRA and idarubicin backbone, with scheduling designed to exploit

61 ting therapy, 562 received ATRA-ATO, and 747 idarubicin-based chemotherapy (AIDA-like CHT).

62 Compared with our previously reported ATRA/idarubicin-based protocol (APML3), APML4 patients had st

63 There were 3 patients who also received idarubicin because of a white blood cell (WBC) count of

64 ash, and mucositis on the troxacitabine plus idarubicin combination.

65 , granulocyte colony-stimulating factor, and idarubicin combined with the B-cell lymphoma-2 inhibitor

66 assigned to receive 2 induction cycles with idarubicin, cytarabine, and all-trans retinoic acid eith

67 assigned up front for induction therapy with idarubicin, cytarabine, etoposide, and all-trans-retinoi

68 o 7) combined with cytarabine (days 1-2) and idarubicin (day 1).

69 Conclusion An increased cumulative dose of idarubicin during consolidation therapy for adult AML re

70 oxide-based regimen that included 4 doses of idarubicin during induction therapy only and no maintena

71 ients with high-risk APL received 4 doses of idarubicin during induction therapy only.

72 Conclusion Idarubicin-eluting beads showed a good safety profile an

73 ncluded in the trial and underwent TACE with idarubicin-eluting beads.

74 2 patients) to receive fludarabine + ara-C + idarubicin (FAI) alone, FAI + ATRA, FAI + G-CSF, or FAI

75 fludarabine, 4 g/m2 cytarabine, and 36 mg/m2 idarubicin [FAI]) and a more myelosuppressive, reduced-i

76 , granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) could improve response and optimis

77 e, granulocyte colony-stimulating factor and idarubicin (FLAG-Ida) or DA with cladribine (DAC).

78 , granulocyte colony-stimulating factor, and idarubicin (FLAG-Ida; n = 1268), and to amsacrine, cytar

79 , granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara

80 CCG-2961 incorporated 3 new agents, idarubicin, fludarabine and interleukin-2, into a phase

81 nts, 60 patients (45%) required either GO or idarubicin for leukocytosis.

82 (CCG-0922) to determine a tolerable dose of idarubicin given with fludarabine and cytarabine in chil

83 Overall, 57 patients in the ATRA and idarubicin group and 40 patients in the ATRA and arsenic

84 d in 25 (28%) of 89 patients in the ATRA and idarubicin group versus 2 (3%) of 77 in the ATRA and ars

85 d in 23 (23%) of 98 patients in the ATRA and idarubicin group versus 5 (5%) of 95 in the ATRA and ars

86 survival was 35.9% (95% CI 25.9-45.9) in the idarubicin group versus 64.6% (54.2-73.2) in the mitoxan

87 In the ATRA and idarubicin group, idarubicin was given intravenously at

88 pportive care than did those in the ATRA and idarubicin group.

89 Idarubicin has been added in 3 patients, with this addit

90 Doxorubicin, daunorubicin, epirubicin, and idarubicin have been in clinical use for decades, but th

91 nduction regimen of cytosine arabinoside and idarubicin hydrochloride, with regression of gingival en

92 clines: Doxorubicin (DOX), Epirubicin (EPI), Idarubicin (IDA) and Daunorubicin (DAU) were examined.

93 l combination of D-penicillamine (D-pen) and Idarubicin (Ida) in a synthetic dual drug conjugate (DDC

94 L-cysteine capped Mn doped ZnS quantum dots/ Idarubicin (IDA) nanohybrids were used as novel room tem

95 Randomized comparisons of idarubicin (IDA) with daunorubicin (DNR) show that in ad

96 cellular accumulation and retention of ANN, idarubicin (IDR), and DOX in the p-gp-negative human leu

97 s tested for sensitivity to various doses of idarubicin (IDR), daunorubicin (DNR), or mitoxantrone (M

98 he combination of sorafenib, cytarabine, and idarubicin in patients with acute myeloid leukemia (AML)

99 Partial replacement of daunomycin with idarubicin in the 5-drug induction combination achieved

100 tandard chemotherapy-based regimen (ATRA and idarubicin) in both high-risk and low-risk patients with

101 n and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of

102 nts (85%) were randomly assigned to L-DNR or idarubicin induction.

103 usion 2000 mg/m(2) per day on days 2-6), and idarubicin (intravenous infusion 10 mg/m(2) per day on d

104 Idarubicin-loaded beads for transarterial chemoembolizat

105 R), safety, and survival after TACE by using idarubicin-loaded beads for unresectable HCC.

106 As compared with idarubicin, mitoxantrone conferred a significant benefit

107 rate dose of IL-2 after high-dose cytarabine-idarubicin-mobilized ASCT is associated with a low regim

108 e enrolled and randomly assigned to ATRA and idarubicin (n=119) or ATRA and arsenic trioxide (n=116).

109 or 8 to 21 of a 7 + 3 induction with either idarubicin or daunorubicin and from day 1 continuously w

110 ed patients were allocated to receive either idarubicin or mitoxantrone in induction by stratified co

111 ll patients were allocated to receive either idarubicin or mitoxantrone in induction by stratified co

112 and an anthracycline such as daunorubicin or idarubicin or the anthracenedione mitoxantrone.

113 of its combination with cytarabine (ara-C), idarubicin, or topotecan.

114 Only 1 L-DNR and 3 idarubicin patients presented with subclinical or mild c

115 l survival 76% +/- 3% [L-DNR] vs 75% +/- 3% [idarubicin], Plogrank = .65; event-free survival [EFS] 5

116 a phase II trial of the experimental regimen idarubicin plus cytarabine (ara-C) plus cyclosporine for

117 n, dexamethasone) plus imatinib/dasatinib or idarubicin plus cytarabine (Ara-C); 2 did not respond, 1

118 We compared GO with or without IL-11 with idarubicin plus cytosine arabinoside (IA), as previously

119 cluded were ALLG APML3 (single arm of ATRA + idarubicin +/- prednisone), ALLG APML4 (single arm of AT

120 overall antileukemic activity comparable to idarubicin, promises to be more active in subgroups, and

121 Subsequently, however, overall (+/- idarubicin) rates of PCR positivity were 0/12 at 3 month

122 , granulocyte colony-stimulating factor, and idarubicin) regimen was associated with improved outcome

123 acyclines, we expected a higher clearance of idarubicin than of doxorubicin.

124 rst induction cycle and reducing the dose of idarubicin, these toxicities dropped to rates observed i

125 e aglycone of the FDA approved anthracycline idarubicin, through the judicious orchestration of Co- a

126 bine and ara-C (TA) versus troxacitabine and idarubicin (TI).

127 lines, including daunomycin, adriamycin, and idarubicin, to build alternate disaccharides on variant

128 After complete remission had been achieved, idarubicin (two days) and cytarabine (five days) were ad

129 , granulocyte colony-stimulating factor, and idarubicin + venetoclax represents an effective intensiv

130 The 10% inhibitory concentration (IC(10)) of idarubicin was 0.5 nM in MOLT4 and 1.5 nM in HL60 cells.

131 arg (9 mg/m(2) every 4 to 5 weeks) and ATRA; idarubicin was added only for persistent or recurrent po

132 Idarubicin was given at three dose levels: 6, 9, and 12

133 In the ATRA and idarubicin group, idarubicin was given intravenously at 12 mg/m(2) on days

134 y equimolar concentrations of epirubicin and idarubicin was significantly less than that of doxorubic

135 ackground A prior in vitro study showed that idarubicin was the most cytotoxic agent for hepatocellul

136 ue uptakes of doxorubicin, daunorubicin, and idarubicin were measured.

137 Among patients who had not received idarubicin when the PCR was evaluated, 0 of 12 were PCR-

138 The combination of idarubicin with vorinostat at 0.075 microM or VPA at 0.2

139 bine, granulocyte colony-stimulating factor, idarubicin) with venetoclax shows promise as frontline p

140 han, and survival not different to, ATRA and idarubicin, with a low incidence of liver toxicity.